Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab.
CI, cardiac index
GI, gastrointestinal tract
HHT, hereditary hemorrhagic telangiectasia
HOCF, high-output cardiac failure
IV, intravenous
LAAC, left atrial appendage closure
TTE, transthoracic echocardiography
Journal
Mayo Clinic proceedings. Innovations, quality & outcomes
ISSN: 2542-4548
Titre abrégé: Mayo Clin Proc Innov Qual Outcomes
Pays: Netherlands
ID NLM: 101728275
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
15
8
2020
pubmed:
15
8
2020
medline:
15
8
2020
Statut:
epublish
Résumé
Bevacizumab is now an emerging treatment option for severe hereditary hemorrhagic telangiectasia-related bleeding including epistaxis and gastrointestinal tract bleeding. The impact of long-term intravenous bevacizumab therapy on cardiac structure and function is unknown. We describe 3 patients receiving intravenous bevacizumab therapy for severe hereditary hemorrhagic telangiectasia-related bleeding who were found to have abnormal mobile masses on the mitral valve (n=2) and aortic valve (n=1). The clinical impact of these findings is unknown and requires further study.
Identifiants
pubmed: 32793873
doi: 10.1016/j.mayocpiqo.2020.01.002
pii: S2542-4548(20)30020-5
pmc: PMC7411168
doi:
Types de publication
Case Reports
Langues
eng
Pagination
460-463Informations de copyright
© 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.
Références
Orphanet J Rare Dis. 2019 Feb 4;14(1):28
pubmed: 30717761
Mayo Clin Proc. 2018 Feb;93(2):155-166
pubmed: 29395350
Am Heart J. 1996 Jun;131(6):1175-83
pubmed: 8644598
World J Gastroenterol. 2015 Apr 28;21(16):5072-80
pubmed: 25945023
Cardiovasc Hematol Disord Drug Targets. 2010 Jun;10(2):84-6
pubmed: 20397972
J Intern Med. 2019 Feb;285(2):223-231
pubmed: 30191646
Am Heart J. 2003 Sep;146(3):404-10
pubmed: 12947356
Clujul Med. 2017;90(4):377-384
pubmed: 29151784
Ann Am Thorac Soc. 2016 Sep;13(9):1505-11
pubmed: 27387823
Oncotarget. 2016 Dec 13;7(50):82473-82481
pubmed: 27756883
JAMA. 2012 Mar 7;307(9):948-55
pubmed: 22396517
J Am Coll Cardiol. 1995 Dec;26(7):1713-8
pubmed: 7594108
J Gastrointest Oncol. 2017 Jun;8(3):485-498
pubmed: 28736636
J Nephrol. 2017 Apr;30(2):171-180
pubmed: 27154025
Lancet. 2014 Mar 1;383(9919):815
pubmed: 24529558